VolitionRx (NYSE:VNRX) Now Covered by StockNews.com

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued to investors on Wednesday. The firm issued a sell rating on the stock.

A number of other analysts have also recently weighed in on the stock. D. Boral Capital reissued a “buy” rating and issued a $5.00 target price on shares of VolitionRx in a research note on Wednesday, January 8th. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Trading Down 4.5 %

VNRX opened at $0.63 on Wednesday. The firm’s fifty day moving average price is $0.66 and its two-hundred day moving average price is $0.66. VolitionRx has a fifty-two week low of $0.43 and a fifty-two week high of $1.23.

Insider Activity

In other VolitionRx news, CEO Cameron John Reynolds purchased 139,811 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was purchased at an average cost of $0.57 per share, with a total value of $79,692.27. Following the acquisition, the chief executive officer now directly owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Guy Archibald Innes acquired 174,764 shares of VolitionRx stock in a transaction on Monday, December 9th. The stock was acquired at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the purchase, the director now owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. This represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 358,266 shares of company stock worth $204,212. Corporate insiders own 12.80% of the company’s stock.

Institutional Trading of VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC boosted its stake in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent SEC filing. 8.09% of the stock is currently owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.